📣 VC round data is live. Check it out!

Haier Biomedical Valuation Multiples

Discover revenue and EBITDA valuation multiples for Haier Biomedical and similar public comparables like Savaria, SKAN Group, El.En. Group, Anbio Biotechnology and more.

Haier Biomedical Overview

About Haier Biomedical

Qingdao Haier Biomedical Co Ltd is engaged in designing, manufacturing, marketing and sales of low temperature storage equipment for biomedical samples. The company provides provides complete storage solutions for biological sample banks, blood safety, vaccine safety, medical supplies and reagent safety.


Founded

2005

HQ

China

Employees

N/A

Financials (LTM)

Revenue: $355M
EBITDA: $59M

EV

$1B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Haier Biomedical Financials

Haier Biomedical reported last 12-month revenue of $355M and EBITDA of $59M.

In the same LTM period, Haier Biomedical generated $166M in gross profit, $59M in EBITDA, and $39M in net income.

Revenue (LTM)


Haier Biomedical P&L

In the most recent fiscal year, Haier Biomedical reported revenue of $344M and EBITDA of $58M.

Haier Biomedical is profitable as of last fiscal year, with gross margin of 47%, EBITDA margin of 17%, and net margin of 11%.

See analyst estimates for Haier Biomedical
LTMLast FY202320242025202620272028
Revenue$355M$344M$337M$338M$344M
Gross Profit$166M$161M$171M$162M$161M
Gross Margin47%47%51%48%47%
EBITDA$59M$58M$80M$78M$58M
EBITDA Margin17%17%24%23%17%
EBIT Margin12%11%15%15%10%
Net Profit$39M$37M$60M$54M$37M
Net Margin11%11%18%16%11%

Financial data powered by Morningstar, Inc.

Haier Biomedical Stock Performance

Haier Biomedical has current market cap of $1B, and enterprise value of $1B.

Market Cap Evolution


Haier Biomedical's stock price is $4.57.

Haier Biomedical share price decreased by 1.4% in the last 30 days, and increased by 2.0% in the last year.

Haier Biomedical has an EPS (earnings per share) of $0.12.

See more trading valuation data for Haier Biomedical
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$1B$1B-2.1%-1.4%-0.1%2.0%$0.12

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Haier Biomedical Valuation Multiples

Haier Biomedical trades at 3.5x EV/Revenue multiple, and 21.2x EV/EBITDA.

See NTM and 2027E valuation multiples for Haier Biomedical

EV / Revenue (LTM)


Haier Biomedical Financial Valuation Multiples

As of June 3, 2026, Haier Biomedical has market cap of $1B and EV of $1B.

Haier Biomedical has a P/E ratio of 37.0x.

LTMLast FY202320242025202620272028
EV/Revenue3.5x3.6x3.7x3.7x3.6x
EV/EBITDA21.2x21.3x15.5x16.0x21.3x
EV/EBIT29.7x32.3x25.1x24.5x35.9x
EV/Gross Profit7.5x7.7x7.3x7.7x7.7x
P/E37.0x39.1x24.1x26.7x39.1x
EV/FCF-56.6x116.7x51.0x56.6x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Haier Biomedical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Haier Biomedical Margins & Growth Rates

Haier Biomedical grew revenue by 10% and EBITDA by 15% in the last fiscal year.

In the most recent fiscal year, Haier Biomedical reported gross margin of 47%, EBITDA margin of 17%, and net margin of 11%.

See estimated margins and future growth rates for Haier Biomedical

Haier Biomedical Margins

Last FY202420252026202720282029
Gross Margin47%48%47%47%
EBITDA Margin17%23%17%18%
EBIT Margin11%15%10%12%
Net Margin11%16%11%11%
FCF Margin6%7%6%-

Haier Biomedical Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth10%0%2%10%
Gross Profit Growth10%(5%)(1%)10%
EBITDA Growth15%(3%)(25%)15%
EBIT Growth20%2%(32%)34%
Net Profit Growth16%(10%)(32%)16%
FCF Growth-129%(10%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

Haier Biomedical Operational KPIs

Haier Biomedical's Rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Haier Biomedical's Rule of X is 43% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Haier Biomedical
LTMLast FY202320242025202620272028
Rule of 4028%28%---
Bessemer Rule of X46%43%---
S&M Expenses to Revenue15%15%6%5%7%
G&A Expenses to Revenue8%8%2%2%2%
R&D Expenses to Revenue14%14%14%13%14%
Opex to Revenue-37%36%33%37%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Haier Biomedical Competitors

Haier Biomedical competitors include Savaria, SKAN Group, El.En. Group, Anbio Biotechnology, Staar Surgical, Vitrolife, Nihon Kohden, Poly Medicure, Nolato and Weigao Group.

Most Haier Biomedical public comparables operate across Laboratory Services, Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Savaria2.4x2.3x11.6x11.2x
SKAN Group3.5x3.3x30.5x25.9x
El.En. Group1.8x1.8x11.9x11.4x
Anbio Biotechnology162.7x-244.0x-
Staar Surgical3.9x4.6x23.7x67.3x
Vitrolife3.9x3.9x13.4x13.1x
Nihon Kohden0.9x0.9x7.8x8.1x
Poly Medicure6.8x6.6x22.9x27.5x

This data is available for Pro users. Sign up to see all Haier Biomedical competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Haier Biomedical

When was Haier Biomedical founded?Haier Biomedical was founded in 2005.
Where is Haier Biomedical headquartered?Haier Biomedical is headquartered in China.
Is Haier Biomedical publicly listed?Yes, Haier Biomedical is a public company listed on Shanghai Stock Exchange.
What is the stock symbol of Haier Biomedical?Haier Biomedical trades under 688139 ticker.
When did Haier Biomedical go public?Haier Biomedical went public in 2019.
Who are competitors of Haier Biomedical?Haier Biomedical main competitors include Savaria, SKAN Group, El.En. Group, Anbio Biotechnology, Staar Surgical, Vitrolife, Nihon Kohden, Poly Medicure, Nolato, Weigao Group.
What is the current market cap of Haier Biomedical?Haier Biomedical's current market cap is $1B.
What is the current revenue of Haier Biomedical?Haier Biomedical's last 12 months revenue is $355M.
What is the current revenue growth of Haier Biomedical?Haier Biomedical revenue growth (NTM/LTM) is 12%.
What is the current EV/Revenue multiple of Haier Biomedical?Current revenue multiple of Haier Biomedical is 3.5x.
What is the current EBITDA of Haier Biomedical?Haier Biomedical's last 12 months EBITDA is $59M.
What is Haier Biomedical's EBITDA margin?Haier Biomedical's last 12 months EBITDA margin is 17%.
What is the current EV/EBITDA multiple of Haier Biomedical?Current EBITDA multiple of Haier Biomedical is 21.2x.
How many companies Haier Biomedical has acquired to date?Haier Biomedical hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Haier Biomedical has invested to date?Haier Biomedical hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Haier Biomedical

Lists including Haier Biomedical

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial